首頁 > 市場調查報告書 > 醫療設備

呼吸器

市場調查報告書

商品編碼

1415691

2024年氣道可逆疾病治療全球市場報告

Reversible Airway Diseases Treatment Global Market Report 2024

出版日期: 按訂單生產 | 出版商:

The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄

近年來，氣道可逆疾病治療市場規模強勁成長。從2023年的794.3億美元增加到2024年的855.3億美元，複合年成長率為7.7%。業績期間的成長是由於氣道可逆性疾病盛行率上升、人們對氣道可逆性疾病的認知提高、獲得醫療保健的機會增加以及可支配收入增加。

氣道可逆疾病治療市場規模預計在未來幾年將強勁成長。到2028年，這一數字將以6.6%的年複合成長率（CAGR）成長至1,102.8億美元。預測期內的成長是由於人口老化、慢性病盛行率上升、都市化和空氣污染加劇以及醫療保健覆蓋率擴大。預測期內的主要趨勢包括數位健康技術的進步、新治療方法的研發、早期療育和預防以及吸入器技術。

慢性呼吸道疾病的盛行率不斷上升被認為是在可預見的未來氣道可逆疾病治療市場擴大的關鍵驅動力。慢性呼吸系統疾病包括影響呼吸系統的多種疾病，呼吸系統由肺部、支氣管、氣管、喉、咽和鼻腔組成。慢性呼吸系統疾病的檢測和治療起著至關重要的作用，特別是在急性呼吸窘迫症候群等疾病的早期發現和診斷方面。及時介入和有效管理可降低這些疾病併發症和進展的風險。例如，根據瑞士民間社會組織非傳染性疾病死亡聯盟的資料，截至 2021 年 2 月，肺癌是全球癌症相關死亡的主要原因，新患者220 萬，死亡人數達 180 萬人。此外，根據《柳葉刀》2022年9月公佈的資料，2021年新增呼吸道融合細胞病毒病例11,255例，比2020年報告的9,972例增加了11.4%。因此，慢性呼吸道疾病盛行率的上升預計將推動氣道可逆疾病治療市場的成長。

預計不斷成長的醫療保健支出將成為未來幾年氣道可逆疾病治療市場成長的主要動力。醫療保健支出包括特定醫療保健系統或經濟體在特定時期內分配給醫療保健服務和相關活動的財政資源總額。衛生支出的成長趨勢在治療氣道可逆性疾病方面尤其重要，因為它們推動了對研發、病患教育、先進藥物的取得和最尖端科技開發的投資增加。因此，增加醫療支出將有助於改善受可逆性氣道疾病影響的患者的管理和結果。例如，截至2022年11月，加拿大衛生組織加拿大健康資訊研究所（CIHI）的報告指出，2021年加拿大的醫療保健支出將達到3,280億美元，隨後在2022年增加至3,310億美元。因此，急劇上升的醫療成本正在推動氣道可逆疾病治療市場的擴張。

2023年，北美是氣道可逆疾病治療市場中最大的地區。預計亞太地區將成為預測期內成長最快的地區。氣道可逆疾病治療報告涵蓋的地區包括亞太地區、西歐、中歐和東歐、北美、南美和中東/非洲。

全球氣道可逆疾病治療市場，依治療、表現及預測細分，2018-2023、2023-2028、2033
胸部X光檢查
電腦斷層掃描 (CT) 掃描
肺部治療
手術植入
藥品
全球氣道可逆疾病治療市場，依疾病、表現及預測細分，2018-2023、2023-2028、2033
氣喘
慢性支氣管炎
氣腫
囊腫纖維化
細支氣管炎
其他
全球氣道可逆疾病治療市場，依最終用戶細分、績效和預測，2018-2023、2023-2028、2033
醫院
專科診所
其他

第 7 章區域與國家分析

全球氣道可逆疾病治療市場，按地區、績效及預測，2018-2023、2023-2028、2033
全球氣道可逆疾病治療市場，依國家、績效及預測，2018-2023、2023-2028、2033

第8章亞太市場

第9章中國市場

第10章印度市場

第11章日本市場

第12章澳洲市場

第13章印尼市場

第14章韓國市場

第15章西歐市場

第16章英國市場

第17章德國市場

第18章法國市場

第19章義大利市場

第20章西班牙市場

第21章東歐市場

第22章俄羅斯市場

第23章北美市場

第24章美國市場

第25章加拿大市場

第26章南美洲市場

第27章巴西市場

第28章中東市場

第29章非洲市場

第30章競爭形勢及公司概況

氣道可逆疾病治療市場競爭形勢
氣道可逆疾病治療市場公司概況
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Merck &Co. Inc.
- AbbVie Inc.
- Novartis AG

第31章其他重大及創新企業

Sanofi SA
GlaxoSmithKline Plc
Medtronic plc
Eli Lilly and Company
Gilead Sciences Inc.
Amgen Inc.
Boehringer Ingelheim International GmbH
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Grifols SA
Sumitomo Dainippon Pharma Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Dragerwerk AG & Co. KGaA
Dr. Reddy's Laboratories Ltd.
Cipla Limited

第32章競爭基準化分析

第 33 章. 競爭對手儀表板

第34章重大併購

第35章未來前景與可能性分析

第36章附錄

簡介目錄

Product Code: r12290

“Reversible Airway Diseases Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on reversible airway diseases treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for reversible airway diseases treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The reversible airway diseases treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Treatment : Chest X Ray; Computed Tomography (CT) Scan; Lung Therapies; Surgery Transplant; Medications
2) By Diseases: Asthma; Chronic Bronchitis; Emphysema; Cystic Fibrosis; Bronchiolitis; Other Diseases
3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Reversible airway diseases refer to conditions characterized by the temporary narrowing of airways, typically caused by inflammation and constriction of the surrounding smooth muscles. The primary objective of treating these conditions is to alleviate symptoms like cough and shortness of breath in order to enhance lung function.

The main categories of treatment options for reversible airway diseases include diagnostic procedures such as chest X-rays and computed tomography (CT) scans, therapeutic lung interventions, surgical procedures, organ transplants, and medications. A chest X-ray is a diagnostic imaging method that employs a small amount of ionizing radiation to produce images of the chest's internal structures, encompassing the heart, lungs, and bones. Various reversible airway diseases include asthma, chronic bronchitis, emphysema, cystic fibrosis, bronchiolitis, and others. These treatment approaches are utilized by diverse end-users, including hospitals, specialty clinics, and other healthcare facilities.

The reversible airway diseases treatment market research report is one of a series of new reports from The Business Research Company that provides reversible airway diseases treatment market statistics, including reversible airway diseases treatment industry global market size, regional shares, competitors with a reversible airway diseases treatment market share, detailed reversible airway diseases treatment market segments, market trends and opportunities and any further data you may need to thrive in the reversible airway diseases treatment industry. This reversible airway diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The reversible airway diseases treatment market size has grown strongly in recent years. It will grow from $79.43 billion in 2023 to $85.53 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to rising prevalence of reversible airway diseases, growing awareness of reversible airway diseases, increasing access to healthcare, rising disposable incomes.

The reversible airway diseases treatment market size is expected to see strong growth in the next few years. It will grow to $110.28 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to aging population, increasing prevalence of chronic diseases, rising urbanization and air pollution, expanding access to healthcare. Major trends in the forecast period include digital health technologies, research and development of new treatments, early intervention and prevention, inhaler technology advancements.

The increasing prevalence of chronic respiratory diseases is poised to be a significant driver of the reversible airway disease treatment market's expansion in the foreseeable future. Chronic respiratory diseases encompass a range of medical conditions affecting the respiratory system, comprising the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. The testing and treatment of chronic respiratory diseases play a pivotal role in early detection and diagnosis, particularly for conditions like acute respiratory distress syndrome. Timely intervention and effective management reduce the risk of complications and the progression of these diseases. For example, as of February 2021, data from the NCD Alliance, a Switzerland-based civil society organization, reveals that lung cancer stands as the primary cause of cancer-related deaths on a global scale, accounting for 2.2 million new cases and 1.8 million fatalities. Furthermore, the data published by The Lancet in September 2022 indicates that there were 11,255 new cases of respiratory syncytial virus in 2021, marking an 11.4% increase from the 9,972 cases reported in 2020. Hence, the escalating incidence of chronic respiratory diseases is anticipated to drive the growth of the reversible airway disease treatment market.

The growing healthcare expenditure is poised to be a key driver of the reversible airway disease treatment market's growth in the coming years. Healthcare expenditure encompasses the total financial resources allocated to healthcare services and associated activities within a specific healthcare system or economy over a defined period. The upward trend in healthcare spending is particularly significant in the context of treating reversible airway diseases, as it facilitates increased investments in research and development, patient education, access to advanced medications, and the development of cutting-edge technologies. Consequently, higher healthcare expenditures contribute to enhancing the management and treatment outcomes for individuals affected by reversible airway diseases. For example, as of November 2022, according to a report by the Canadian Institute for Health Information (CIHI), a Canada-based health organization, Canada's healthcare expenditure reached $328 billion in 2021 and subsequently increased to $331 billion in 2022. Thus, the escalating healthcare expenditures are propelling the expansion of the reversible airway disease treatment market.

The restricted availability of vital inhaled therapies for individuals with COPD in low and middle-income countries (LMICs) is posing a hurdle to the growth of the reversible airway disease treatment market. Inhalation therapy is a medical approach that enables the direct delivery of medications into the airways via inhalation devices. However, in LMICs, there is a lack of access to and affordability of crucial inhaled therapies for individuals with COPD, which can limit their ability to receive effective treatment options. For example, as of October 2022, data from the Lancet Global Health indicated that only six out of 58 countries achieved the 80% availability target for short-acting beta-agonists (SABAs), and merely three out of 48 met the minimum requirement for inhaled corticosteroids (ICSs). Consequently, the inadequate accessibility of essential inhaled therapies for COPD patients in low- and middle-income countries (LMICs) is impeding the advancement of the reversible airway disease treatment market.

The prominent companies within the reversible airway disease treatment market are placing a significant emphasis on inhalation-based dosage forms for respiratory drug delivery to maintain their market presence. For instance, in June 2021, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Tiogiva, a Tiotropium Bromide Dry Powder Inhaler (DPI) in the United Kingdom. Tiogiva is a bioequivalent alternative to Boehringer Ingelheim's Spiriva Handihaler, designed for managing chronic obstructive pulmonary disease (COPD). COPD is a chronic condition characterized by lung inflammation, damage to lung tissue, and airway constriction. Glenmark Pharmaceuticals has plans to expand the product's availability throughout Western Europe, introducing it under various brand names such as Tiogiva in Ireland, Sweden, Finland, and Norway; Tavulus in Denmark, Spain, and the Netherlands; and Tiotropium Glenmark in Germany.

In October 2022, Lupin Ltd., an India-based pharmaceutical company, completed the purchase of two inhalation product brands from Sunovion Pharmaceuticals Inc. for $75 million. This strategic acquisition is set to fortify Lupin Ltd.'s inhalation product portfolio, with the addition of two brands, including Brovana (arformoterol tartrate) inhalation solution. Brovana is specifically indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including those with reversible obstructive airway disease. The move serves to enhance Lupin Ltd.'s presence in the field of respiratory therapy. Sunovion Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the treatment of reversible airway diseases.

Major players in the reversible airway diseases treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline Plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Grifols SA, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Dragerwerk AG & Co. KGaA, Dr. Reddy's Laboratories Ltd., Cipla Limited, Getinge AB, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Fisher & Paykel Healthcare Corporation Limited .

North America was the largest region in the reversible airway diseases treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in reversible airway disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the reversible airway disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The reversible airway disease treatment market consists of sales of biological therapies and oxygen therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The reversible airway disease treatment market also includes sales of anti-inflammatory drugs, monoclonal antibody drugs and medical devices such as inhaler devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

1. Executive Summary

2. Reversible Airway Diseases Treatment Market Characteristics

3. Reversible Airway Diseases Treatment Market Trends And Strategies

4. Reversible Airway Diseases Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Reversible Airway Diseases Treatment Market Size and Growth

5.1. Global Reversible Airway Diseases Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Reversible Airway Diseases Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Reversible Airway Diseases Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Reversible Airway Diseases Treatment Market Segmentation

6.1. Global Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Chest X Ray
Computed Tomography (CT) Scan
Lung Therapies
Surgery Transplant
Medications
6.2. Global Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Asthma
Chronic Bronchitis
Emphysema
Cystic Fibrosis
Bronchiolitis
Other Diseases
6.3. Global Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Specialty Clinics
Other End-Users

7. Reversible Airway Diseases Treatment Market Regional And Country Analysis

7.1. Global Reversible Airway Diseases Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Reversible Airway Diseases Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Reversible Airway Diseases Treatment Market

8.1. Asia-Pacific Reversible Airway Diseases Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Reversible Airway Diseases Treatment Market

9.1. China Reversible Airway Diseases Treatment Market Overview
9.2. China Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Reversible Airway Diseases Treatment Market

10.1. India Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Reversible Airway Diseases Treatment Market

11.1. Japan Reversible Airway Diseases Treatment Market Overview
11.2. Japan Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Reversible Airway Diseases Treatment Market

12.1. Australia Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Reversible Airway Diseases Treatment Market

13.1. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Reversible Airway Diseases Treatment Market

14.1. South Korea Reversible Airway Diseases Treatment Market Overview
14.2. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Reversible Airway Diseases Treatment Market

15.1. Western Europe Reversible Airway Diseases Treatment Market Overview
15.2. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Reversible Airway Diseases Treatment Market

16.1. UK Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Reversible Airway Diseases Treatment Market

17.1. Germany Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Reversible Airway Diseases Treatment Market

18.1. France Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Reversible Airway Diseases Treatment Market

19.1. Italy Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Reversible Airway Diseases Treatment Market

20.1. Spain Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Reversible Airway Diseases Treatment Market

21.1. Eastern Europe Reversible Airway Diseases Treatment Market Overview
21.2. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Reversible Airway Diseases Treatment Market

22.1. Russia Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Reversible Airway Diseases Treatment Market

23.1. North America Reversible Airway Diseases Treatment Market Overview
23.2. North America Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Reversible Airway Diseases Treatment Market

24.1. USA Reversible Airway Diseases Treatment Market Overview
24.2. USA Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Reversible Airway Diseases Treatment Market

25.1. Canada Reversible Airway Diseases Treatment Market Overview
25.2. Canada Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Reversible Airway Diseases Treatment Market

26.1. South America Reversible Airway Diseases Treatment Market Overview
26.2. South America Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Reversible Airway Diseases Treatment Market

27.1. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Reversible Airway Diseases Treatment Market

28.1. Middle East Reversible Airway Diseases Treatment Market Overview
28.2. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Reversible Airway Diseases Treatment Market

29.1. Africa Reversible Airway Diseases Treatment Market Overview
29.2. Africa Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Reversible Airway Diseases Treatment Market Competitive Landscape And Company Profiles

30.1. Reversible Airway Diseases Treatment Market Competitive Landscape
30.2. Reversible Airway Diseases Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Reversible Airway Diseases Treatment Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. GlaxoSmithKline Plc
31.3. Medtronic plc
31.4. Eli Lilly and Company
31.5. Gilead Sciences Inc.
31.6. Amgen Inc.
31.7. Boehringer Ingelheim International GmbH
31.8. Viatris Inc.
31.9. Teva Pharmaceutical Industries Ltd.
31.10. Grifols SA
31.11. Sumitomo Dainippon Pharma Co. Ltd.
31.12. Sun Pharmaceutical Industries Ltd.
31.13. Dragerwerk AG & Co. KGaA
31.14. Dr. Reddy's Laboratories Ltd.
31.15. Cipla Limited

32. Global Reversible Airway Diseases Treatment Market Competitive Benchmarking

33. Global Reversible Airway Diseases Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Reversible Airway Diseases Treatment Market

35. Reversible Airway Diseases Treatment Market Future Outlook and Potential Analysis

35.1 Reversible Airway Diseases Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Reversible Airway Diseases Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Reversible Airway Diseases Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies